# SK Bioscience signs 39.4 billion won vaccine supply deal with Novavax

SK Bioscience announced a 39.4 billion won contract with Novavax to produce and supply COVID-19 vaccine in prefilled syringe (PFS) formulation.

- Type: Contract
- Announced: 2022-07-19
- Where: South Korea
- Value: $30.0M (39.4B KRW)
- Status: announced
- Products: COVID-19 vaccine prefilled syringe

## Companies

- [SK Bioscience](https://endata.com/companies/55971.md)
- [Novavax](https://endata.com/companies/64232.md) (customer)

## Sources

- [fnnews.com](https://www.fnnews.com/news/202207190917049679), 2022-07-19: "SK바이오사이언스는 노바백스와 394억원 규모로 코로나19 백신의 프리필드시린지(PFS, 사전충전형 주사기) 제형 생산 공급계약을 체결했다고 19일 공시했다."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.